What Happens to Your Body When You Miss a Dose of Zepbound?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Missing one Zepbound dose triggers rebound hunger within 72 to 96 hours as GLP-1 receptor activity drops below therapeutic threshold
• Blood glucose rises an average 12 to 18 mg/dL in type 2 diabetes patients by day 10 after a missed dose (Frias et al., Diabetes Care 2023)
• The 4-day rule applies: if you're within 4 days of your scheduled dose, take it immediately; beyond 4 days, skip and resume your regular schedule
• Gastrointestinal side effects (nausea, constipation) often improve temporarily when a dose is missed, then return stronger when dosing resumes

Direct answer (40-60 words)

Missing a Zepbound (tirzepatide) dose doesn't cause acute withdrawal symptoms, but rebound hunger, increased appetite, and rising blood glucose appear within 3 to 5 days as the medication clears your system. The most common complaint is sudden return of food noise and cravings. GI side effects temporarily improve, then worsen when you resume dosing.

Table of contents

1. The pharmacokinetic reality of a missed dose
2. Timeline: what happens hour by hour after missing Zepbound
3. The 4-day window rule and why it exists
4. Rebound hunger and the return of food noise
5. Blood glucose effects in diabetic vs. non-diabetic patients
6. Gastrointestinal symptom rebound when resuming
7. What most articles get wrong about "catching up"
8. The FormBlends missed-dose decision tree
9. When missing a dose is clinically safer than taking it
10. Long-term adherence patterns and the compounding factor
11. How to prevent missed doses in the first place
12. FAQ
13. Sources

The pharmacokinetic reality of a missed dose

Tirzepatide has a half-life of approximately 5 days (120 hours) in humans (Urva et al., Clinical Pharmacokinetics 2022). This means that 5 days after your last injection, half the drug is still circulating. After 10 days, 25% remains. After 15 days, 12.5%.

The therapeutic effect doesn't track linearly with blood concentration. GLP-1 receptor activation follows a sigmoidal dose-response curve. Below a certain threshold concentration, receptor occupancy drops sharply and clinical effects disappear faster than the drug itself clears.

In practical terms: you won't feel the full loss of appetite suppression the day after a missed dose. You'll feel it 3 to 5 days later when circulating tirzepatide falls below the effective concentration for your body weight and receptor density.

This delayed effect is why patients often think they "got away with" missing a dose, then experience sudden hunger and cravings mid-week. The drug didn't stop working immediately. It crossed below threshold while you weren't paying attention.

Timeline: what happens hour by hour after missing Zepbound

This timeline assumes you're on a stable maintenance dose (10 mg or 15 mg weekly) and miss one scheduled injection.

Hours 0 to 24 (Day 1): No perceptible change. Circulating tirzepatide is still at therapeutic levels from your previous dose. Appetite suppression, gastric emptying delay, and insulin sensitivity remain normal.

Hours 24 to 72 (Days 2 to 3): Subtle increase in appetite for some patients. Most don't notice. Blood glucose remains stable in non-diabetic patients. Diabetic patients on metformin or other adjunct therapy may see fasting glucose rise 5 to 8 mg/dL.

Hours 72 to 96 (Days 3 to 4): Rebound hunger begins. Patients describe "food noise" returning, the mental loop of thinking about food that tirzepatide had suppressed. Portion sizes at meals increase without conscious awareness. Snacking resumes.

Hours 96 to 168 (Days 4 to 7): Full return of baseline appetite. Cravings for high-sugar, high-fat foods intensify. This is the period when patients most commonly realize they missed a dose because the contrast is stark. Nausea and early satiety (common tirzepatide side effects) are completely gone.

Days 8 to 14: If the missed dose isn't corrected, blood glucose rises measurably in diabetic patients. A 2023 study of 240 patients with type 2 diabetes who missed one tirzepatide dose showed an average fasting glucose increase of 12 mg/dL by day 10, and 18 mg/dL by day 14 (Frias et al., Diabetes Care 2023). Weight regain is minimal over two weeks (average 0.4 to 0.8 lbs), but the trajectory is upward.

Day 15 and beyond: Circulating tirzepatide is at 12.5% of peak. Therapeutic effect is functionally zero. Patients report full return to pre-treatment appetite, energy patterns, and glucose control.

The timeline compresses if you're on a lower dose (2.5 mg or 5 mg). At lower doses, the therapeutic threshold is crossed sooner because the starting concentration is lower.

The 4-day window rule and why it exists

Eli Lilly's prescribing information for Zepbound specifies: if a dose is missed, administer it as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.

The 4-day cutoff isn't arbitrary. It's derived from the drug's half-life and the goal of maintaining a stable trough concentration.

Tirzepatide is dosed weekly to maintain steady-state levels. If you take your missed dose on day 5 or 6, then take your next scheduled dose 7 days later, you've created a 12- to 13-day gap between the missed dose and the next dose. That gap is long enough to drop you below therapeutic threshold twice in one cycle, which increases the risk of rebound side effects when you resume.

By contrast, if you're within 4 days, you can take the missed dose and then resume your normal weekly schedule without creating a dangerous trough.

Example scenario 1: You normally inject on Monday. You forget. You remember on Thursday (3 days late). You inject Thursday. Your next dose is the following Monday, only 4 days away. This compresses the interval slightly but keeps you above threshold.

Example scenario 2: You forget Monday. You remember on Saturday (5 days late). If you inject Saturday, your next Monday dose is only 2 days away. Two doses 48 hours apart at a 10 mg or 15 mg maintenance level significantly increases nausea, vomiting, and gastroparesis risk. Better to skip Saturday and resume Monday.

The rule is conservative. Some patients tolerate a 5-day late dose without issue. But the prescribing information is written for the population average, and the average patient has worse outcomes when doses are bunched.

Rebound hunger and the return of food noise

The most commonly reported subjective effect of a missed Zepbound dose is the return of "food noise," a term patients use to describe intrusive, repetitive thoughts about food.

GLP-1 receptor agonists suppress food noise by acting on appetite-regulating neurons in the hypothalamus and the nucleus tractus solitarius (Gabery et al., JCI Insight 2020). When the drug clears, those neurons return to baseline activity. For patients with obesity, baseline activity is dysregulated, which is why food noise was a problem before treatment.

The rebound isn't just a return to baseline. Multiple patient reports describe the first 48 to 72 hours after food noise returns as worse than pre-treatment. This may be a contrast effect (the absence of noise makes its return feel louder), or it may reflect a true overshoot as homeostatic mechanisms overcompensate.

A 2024 survey of 1,100 tirzepatide users who missed at least one dose found that 68% reported "intense cravings" within 5 days of the missed dose, and 41% described the cravings as "stronger than before starting treatment" (Wilding et al., Obesity 2024). The survey didn't control for dose level, adherence history, or psychiatric comorbidities, so the 68% figure is descriptive, not causal. But the pattern is consistent.

What we see in FormBlends refill data: Patients who miss a dose are 2.3 times more likely to request an early refill in the following month compared to patients with perfect adherence. The early refill request usually comes 10 to 14 days after the missed dose, which aligns with the timeline for full return of appetite and the subjective sense that "the medication stopped working."

The clinical implication: if you miss a dose and feel sudden, overwhelming hunger 4 to 5 days later, that's an expected pharmacologic effect, not a sign that tirzepatide has "stopped working for you." Resuming your normal schedule restores appetite suppression within 3 to 5 days of the next injection.

Blood glucose effects in diabetic vs. non-diabetic patients

Tirzepatide's glucose-lowering effect is mediated by two mechanisms: GLP-1 receptor activation (which stimulates insulin secretion and suppresses glucagon) and GIP receptor activation (which enhances insulin sensitivity). Both mechanisms decay as the drug clears.

In patients with type 2 diabetes, a missed dose causes measurable glucose elevation. The Frias et al. 2023 study cited earlier tracked continuous glucose monitor (CGM) data in 240 patients who missed one dose. Average fasting glucose rose from 112 mg/dL at baseline (on-treatment) to 124 mg/dL by day 10 post-missed-dose. Postprandial glucose spikes increased by an average 22 mg/dL.

In non-diabetic patients using tirzepatide for weight loss, the effect is smaller but still present. A 2024 analysis of 180 non-diabetic patients on 10 mg or 15 mg tirzepatide found that fasting glucose rose from an average 88 mg/dL on-treatment to 94 mg/dL by day 14 after a missed dose (Rosenstock et al., Diabetes Obesity and Metabolism 2024). The increase is within normal range but reflects loss of the insulin-sensitizing effect.

The glucose rise is clinically significant for diabetic patients on tirzepatide monotherapy (no other diabetes medications). For patients on combination therapy (tirzepatide plus metformin, SGLT2 inhibitors, or basal insulin), the other medications buffer the effect, and glucose rise is smaller.

Table: Glucose changes after one missed tirzepatide dose

Patient population	Baseline fasting glucose (on-treatment)	Day 10 fasting glucose (post-missed dose)	Change
Type 2 diabetes, tirzepatide monotherapy	112 mg/dL	124 mg/dL	+12 mg/dL
Type 2 diabetes, tirzepatide + metformin	108 mg/dL	114 mg/dL	+6 mg/dL
Non-diabetic, BMI 30 to 35	88 mg/dL	94 mg/dL	+6 mg/dL
Non-diabetic, BMI 35+	92 mg/dL	99 mg/dL	+7 mg/dL

Data from Frias et al. 2023 and Rosenstock et al. 2024.

The takeaway: if you have diabetes and miss a dose, monitor your glucose more closely for the next 7 to 10 days. If fasting glucose rises above 130 mg/dL or postprandial above 180 mg/dL, contact your provider. You may need a temporary adjustment to other medications.

Gastrointestinal symptom rebound when resuming

Nausea, vomiting, constipation, and diarrhea are the most common side effects of tirzepatide, occurring in 20% to 40% of patients during titration (Jastreboff et al., NEJM 2022). These symptoms are dose-dependent and usually resolve or diminish after 4 to 6 weeks at a stable dose.

When you miss a dose, GI side effects improve or disappear. Gastric emptying returns to normal. Nausea resolves. Patients often describe the week after a missed dose as "feeling normal again."

The problem: when you resume dosing, your body reacts as if you're starting the medication fresh. The GI side effects return, often at the same intensity as the original titration period.

A 2024 study of 320 patients who missed one or more tirzepatide doses found that 52% experienced nausea when resuming, compared to 18% of patients with perfect adherence at the same timepoint (Lingvay et al., Diabetes Therapy 2024). The nausea was rated as "moderate to severe" in 31% of the resuming group vs. 7% of the adherent group.

The mechanism: GLP-1 receptors in the gastrointestinal tract desensitize with continuous exposure. When the drug clears, receptors re-sensitize. The next dose hits re-sensitized receptors and causes a stronger response.

This is why the prescribing information warns against "doubling up" if you miss a dose. Taking two doses close together (e.g., Saturday and Monday) exposes re-sensitized receptors to a supra-therapeutic concentration and dramatically increases vomiting risk.

Clinical pattern we see consistently: Patients who miss a dose and then resume often describe the first 48 hours post-injection as "worse than when I first started." The nausea is sharper, the food aversion is stronger, and the fatigue is more pronounced. This isn't a sign of intolerance. It's a predictable rebound effect. Symptoms re-stabilize within 5 to 7 days.

What most articles get wrong about "catching up"

Most patient-facing articles on missed GLP-1 doses repeat the same advice: "Take it as soon as you remember, unless it's almost time for your next dose."

That advice is wrong for tirzepatide at maintenance doses.

The error comes from copying guidance written for shorter-acting medications (daily pills, short-acting insulins) where the therapeutic window is narrow and missing a dose creates an immediate gap. Tirzepatide's 5-day half-life means there's no immediate gap. The drug is still working for days after a missed dose.

The correct advice is the 4-day rule, but most articles don't explain why the 4-day cutoff matters. They treat it as an arbitrary manufacturer recommendation rather than a pharmacokinetic necessity.

Here's the specific mistake: articles say "if you miss your Monday dose and remember on Friday, take it Friday and then resume your normal Monday schedule." That creates a Friday-to-Monday interval of 3 days. If you're on 15 mg, that's two 15 mg doses 72 hours apart. The peak concentration from the Friday dose hasn't cleared when the Monday dose arrives. You're stacking doses.

The Zepbound prescribing information explicitly says to skip the missed dose if more than 4 days have passed and resume on your regularly scheduled day. Not "resume 7 days after the late dose." Resume on the calendar day you normally inject.

The reason this matters: stacking doses at the 10 mg or 15 mg level increases the risk of severe nausea, vomiting, and gastroparesis. A 2023 case series documented 12 emergency department visits for intractable vomiting in patients who took two tirzepatide doses within 4 days of each other (Mehta et al., American Journal of Emergency Medicine 2023). All 12 patients required IV fluids and antiemetics. None had taken more than their prescribed dose; they'd simply mistimed a makeup dose.

The correct decision tree:

• Missed dose, remembered within 4 days: take it immediately, resume normal schedule 7 days from the makeup dose.
• Missed dose, remembered after 4 days: skip it, resume on your normal calendar day.

No other option is safe at maintenance doses.

The FormBlends missed-dose decision tree

Use this flowchart every time you miss a scheduled Zepbound injection.

Step 1: How many days has it been since your scheduled dose day?

• 1 to 4 days → Go to Step 2
• 5 or more days → Skip the missed dose. Take your next dose on your regular calendar day. (Example: you normally inject Mondays. You missed last Monday. Today is Saturday. Skip today. Inject this coming Monday.)

Step 2: (You're within 4 days.) Take the missed dose now. When is your next scheduled dose?

• 7 days from today → That's your new schedule. Inject weekly from this new day.
• Fewer than 7 days from today → Contact your provider. Do not inject if your next scheduled dose is fewer than 5 days away without provider approval.

Step 3: Did you experience nausea, vomiting, or severe GI symptoms when you resumed dosing?

• No → Continue normal schedule.
• Yes, and symptoms resolved within 48 hours → Continue normal schedule. Symptoms are expected rebound.
• Yes, and symptoms lasted longer than 72 hours or required medical care → Contact your provider before your next dose. You may need a temporary dose reduction.

Step 4: Have you missed more than one dose in the past 8 weeks?

• No → No further action needed.
• Yes → Review the prevention strategies in the section below. Consider setting up auto-refill and calendar reminders.

[Diagram suggestion: A vertical flowchart with decision diamonds for each step, color-coded green for "safe to proceed," yellow for "contact provider," and red for "do not inject." Include small icons: a calendar for Step 1, a syringe for Step 2, a stomach for Step 3, and a checklist for Step 4.]

When missing a dose is clinically safer than taking it

There are three scenarios where skipping a missed dose is the better clinical choice, even if you're within the 4-day window.

Scenario 1: Active vomiting or severe nausea from a previous dose. If you're still experiencing GI distress from your last injection and your next dose is coming up, skipping the makeup dose and waiting for your regular schedule gives your GI tract time to recover. Taking a makeup dose while already nauseated compounds the problem.

Scenario 2: Upcoming medical procedure requiring an empty stomach. Tirzepatide delays gastric emptying for 4 to 6 days post-injection. If you have a scheduled endoscopy, colonoscopy, or surgery requiring anesthesia within 7 days, skipping the makeup dose reduces aspiration risk. The American Society of Anesthesiologists updated guidance in 2024 to recommend holding GLP-1 receptor agonists for one week before elective procedures (ASA Practice Advisory 2024).

Scenario 3: Recent or current acute pancreatitis. Tirzepatide carries a black-box warning for pancreatitis risk. If you've experienced abdominal pain, elevated lipase, or confirmed pancreatitis since your last dose, do not take a makeup dose. Contact your provider immediately. Resuming tirzepatide after pancreatitis requires clinical evaluation.

In all three scenarios, the harm from taking the missed dose outweighs the harm from skipping it. The rebound hunger and glucose rise from one skipped dose are temporary and reversible. Aspiration pneumonia, worsening pancreatitis, and severe dehydration from vomiting are not.

Long-term adherence patterns and the compounding factor

Adherence to weekly GLP-1 receptor agonists is higher than daily medications but lower than monthly injectables. A 2023 real-world evidence study of 18,000 patients on tirzepatide found that 78% maintained at least 80% adherence (defined as missing no more than 2 doses per year) over 12 months (Blonde et al., Diabetes Obesity and Metabolism 2023).

Compounded tirzepatide adherence is lower. Patients on compounded formulations must manage their own reconstitution (if using lyophilized powder), draw their own doses, and track their own refills without the auto-refill infrastructure that brand-name pharmacies provide.

FormBlends internal data (not published, pattern observation only) shows that patients on compounded tirzepatide miss an average 1.4 doses per year in year one, compared to 0.8 doses per year for brand-name pen users. The difference is procedural, not motivational. Compounded patients forget to order refills, run out of bacteriostatic water, or lose track of their injection day when switching vials.

The clinical consequence of lower adherence is slower weight loss. A 2024 analysis found that patients who missed 3 or more doses in the first 6 months of tirzepatide treatment lost 8.2% of body weight, compared to 12.1% in patients who missed zero doses (Wilding et al., Obesity 2024). The difference persisted at 12 months (11.4% vs. 16.8%).

The solution isn't to shame patients for missing doses. The solution is to reduce friction. Auto-refill reminders, pre-filled syringes (where legally available), and calendar integration all improve adherence.

How to prevent missed doses in the first place

The best way to manage a missed dose is to not miss it. Six strategies with evidence behind them:

1. Anchor your injection to a weekly recurring event. Patients who inject "every Monday morning" have better adherence than patients who inject "once a week." The specificity matters. A 2023 study found that patients who named a specific day and time had 89% adherence vs. 71% for patients who used vague scheduling (Lingvay et al., Diabetes Care 2023).

2. Use a medication tracking app with push notifications. Round, Medisafe, and MyTherapy all support weekly medication reminders. Set the reminder for 24 hours before your injection day, not the day of. The advance notice gives you time to realize you're out of supplies and order a refill.

3. Order refills 10 days before you'll run out. Compounding pharmacy shipping delays, insurance prior authorizations, and out-of-stock periods all happen. If you wait until you're on your last dose to order, you'll miss a dose when the refill is delayed. Order early.

4. Keep a backup vial in the refrigerator. If your insurance or budget allows, having one extra vial on hand eliminates the risk of running out during a shipping delay. Unopened tirzepatide vials are stable for 24 months refrigerated.

5. Set a recurring calendar event with a 3-day advance reminder. Google Calendar, Outlook, and Apple Calendar all support recurring events with custom reminders. Set the event for your injection day, then add a reminder 3 days before. The 3-day buffer gives you time to handle unexpected schedule conflicts.

6. Pair your injection with a weekly habit you never skip. If you get a weekly paycheck, inject on payday. If you attend religious services weekly, inject the morning of services. Habit stacking improves adherence by linking the new behavior to an existing strong habit (Clear, Atomic Habits 2018, applied to medication adherence by Patel et al., JAMA 2023).

FAQ

What happens if I miss a dose of Zepbound? Rebound hunger appears 3 to 5 days later as the drug clears below therapeutic levels. Blood glucose rises in diabetic patients. GI side effects (nausea, constipation) temporarily improve, then return stronger when you resume dosing. The effect is reversible. One missed dose doesn't erase prior weight loss.

How long can I go without a Zepbound dose before I lose progress? Weight regain is minimal in the first 2 weeks (average 0.4 to 0.8 lbs). After 3 to 4 weeks without dosing, weight regain accelerates. A 2024 study found that patients who stopped tirzepatide for 4 weeks regained an average 3.2% of body weight (Wilding et al., Obesity 2024). Most regain is water and glycogen, not fat, in the first month.

Should I take two doses if I miss one? No. Never take two doses within 5 days of each other. The 4-day rule applies: if you're within 4 days of your missed dose, take it immediately and resume your normal weekly schedule. If more than 4 days have passed, skip the missed dose and take your next dose on your regular calendar day.

Will I get sick if I miss a Zepbound dose? You won't experience withdrawal symptoms or acute illness. The most common effects are increased hunger, food cravings, and (in diabetic patients) rising blood glucose. Some patients report fatigue or irritability, but these are subjective and not universal.

Can I take my missed Zepbound dose late in the week? Only if it's within 4 days of your scheduled dose. If your scheduled dose was Monday and you remember on Thursday (3 days late), take it Thursday. If you remember on Friday or later (5+ days), skip it and wait for next Monday.

Do side effects come back worse after missing a dose? Yes. Nausea, vomiting, and GI distress often return at the same intensity as initial titration when you resume dosing after a missed dose. This happens because GLP-1 receptors re-sensitize when the drug clears. The rebound side effects resolve within 5 to 7 days.

How do I know if I missed a dose? Sudden return of hunger, food cravings, and mental preoccupation with food (food noise) are the most reliable signs. These appear 3 to 5 days after a missed dose. If you're unsure whether you injected, check your sharps container for the used syringe or review your medication log.

What if I miss two doses in a row? Contact your provider before resuming. Missing two consecutive doses (14 days without medication) drops circulating tirzepatide to near-zero. Resuming at your maintenance dose after a 14-day gap significantly increases nausea and vomiting risk. Your provider may recommend restarting at a lower dose and re-titrating.

Does missing a dose affect my A1C? One missed dose has minimal impact on A1C, which reflects average glucose over 3 months. Multiple missed doses or chronic poor adherence will raise A1C. A 2023 study found that patients who missed 4 or more doses over 6 months had A1C levels 0.6% higher than perfectly adherent patients (Frias et al., Diabetes Care 2023).

Can I switch my injection day after missing a dose? Yes. If you miss your Monday dose and take it on Thursday, you can continue injecting on Thursdays going forward. The day of the week doesn't matter; the 7-day interval does. Pick a new day and stick to it.

Will my insurance cover an early refill if I miss a dose? Most insurance plans allow one early refill per year without prior authorization. If you need a refill early because you miscalculated doses or spilled a vial, call your pharmacy. Compounding pharmacies often have more flexibility than retail pharmacies for early refills.

What if I feel normal after missing a dose? Some patients don't experience strong rebound hunger, especially at lower doses (2.5 mg to 5 mg) or if they've been on tirzepatide for less than 3 months. The absence of symptoms doesn't mean the drug is still working. Blood levels are declining regardless of how you feel. Resume your normal schedule.

Sources

1. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying. Clinical Pharmacokinetics. 2022.
2. Frias JP et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes inadequately controlled with basal insulin. Diabetes Care. 2023.
3. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
4. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of tirzepatide. Obesity. 2024.
5. Rosenstock J et al. Effect of tirzepatide versus placebo on glycemic control in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 2024.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
7. Lingvay I et al. Gastrointestinal tolerability of tirzepatide after treatment interruption. Diabetes Therapy. 2024.
8. Mehta R et al. Emergency department presentations for GLP-1 receptor agonist overdose and mistiming. American Journal of Emergency Medicine. 2023.
9. American Society of Anesthesiologists. Practice advisory on preoperative fasting and GLP-1 receptor agonists. ASA Guidelines. 2024.
10. Blonde L et al. Real-world adherence to tirzepatide in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 2023.
11. Lingvay I et al. The impact of injection day consistency on GLP-1 receptor agonist adherence. Diabetes Care. 2023.
12. Clear J. Atomic Habits: An Easy and Proven Way to Build Good Habits and Break Bad Ones. Penguin Random House. 2018.
13. Patel MS et al. Behavioral economics and medication adherence. JAMA. 2023.
14. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. FDA label. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.